BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 19318306)

  • 1. [Adjuvant breast cancer treatment with hormono-radiotherapy].
    Azria D; Jacot W; Gligorov J; Belkacémi Y; Zaman K; Romieu G; Ozsahin M
    Bull Cancer; 2009 Mar; 96(3):285-9. PubMed ID: 19318306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [How to combine hormonotherapy and radiation treatment in adjuvant breast cancer?].
    Azria D; Ozsahin M; Gligorov J; Zaman K; Llacer Moscardo C; Lemanski C; Jacot W; Belkacémi Y
    Cancer Radiother; 2008 Jan; 12(1):37-41. PubMed ID: 18248833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer].
    Novoa Vargas A; Font López KC; Amador DD
    Ginecol Obstet Mex; 2011 Sep; 79(9):553-7. PubMed ID: 21966856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Letrozole vs. placebo after adjuvant tamoxifen in postmenopausal breast cancer: the MA-17 study].
    Gori S; Anastasi P; Marrocolo F
    Suppl Tumori; 2004; 3(4):S27-31. PubMed ID: 15206206
    [No Abstract]   [Full Text] [Related]  

  • 5. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
    Monnier AM
    Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Interactions between radiation and hormonal therapy in breast cancer: simultaneous or sequential treatment].
    Fodor J
    Orv Hetil; 2006 Jan; 147(3):121-5. PubMed ID: 16515031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    ; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
    N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
    Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Therasse P; Palmer MJ; Pater JL
    N Engl J Med; 2003 Nov; 349(19):1793-802. PubMed ID: 14551341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
    Morandi P; Rouzier R; Altundag K; Buzdar AU; Theriault RL; Hortobagyi G
    Cancer; 2004 Oct; 101(7):1482-9. PubMed ID: 15378476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Letrozole in breast cancer.
    Shahab N
    N Engl J Med; 2004 Feb; 350(7):727-30; author reply 727-30. PubMed ID: 14971058
    [No Abstract]   [Full Text] [Related]  

  • 12. [Adjuvant treatment of breast cancer by concomitant hormonotherapy and radiotherapy: state of the art].
    Azria D; Lemanski C; Zouhair A; Gutowski M; Belkacémi Y; Dubois JB; Romieu G; Ozsahin M
    Cancer Radiother; 2004 Jun; 8(3):188-96. PubMed ID: 15217586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
    Wardley AM
    Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
    Forbes JF
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant aromatase inhibitors: are we there yet?
    Fleming GF
    Cancer; 2003 Nov; 98(9):1779-81. PubMed ID: 14584057
    [No Abstract]   [Full Text] [Related]  

  • 16. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Letrozole vs. placebo after adjuvant tamoxifen in postmenopausal breast cancer. The example of the MA-17 study].
    Forciniti S
    Suppl Tumori; 2004; 3(4):S25-6. PubMed ID: 15206205
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
    Delea TE; El-Ouagari K; Karnon J; Sofrygin O
    Breast Cancer Res Treat; 2008 Apr; 108(3):375-87. PubMed ID: 17653859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.
    Grana G
    J Surg Oncol; 2006 Jun; 93(7):585-92. PubMed ID: 16705732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.